Conclusions
The results of the few preliminary studies make it difficult to assess the utility of PDT or EUS-guided therapy for the treatment of pancreatic cancer. However, these modalities have tremendous potential and deserve further investigation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1998;48:6–29.
Williamson R. Pancreatic cancer: the greatest oncologic challenge. Br Med J. 1991;296:445
Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer: a comparison of 5-FU, adriamycin, and mitomycin C. Cancer. 1986;57:29–33.
Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma [review]. Cancer. 1981;47:1724–1728.
Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer. 1989;64:2010–2013.
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
Dobelbower RR, Merrick HW, Ahuja RK, Skeel RT. I-125 interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of the pancreas and the biliary tree. Cancer. 1986;58:2185–2195.
Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR. Hyperfractionated radiation for unresectable localized adenocarcinoma of the pancreas: the Gastrointestinal Tumor Study Group experience. Cancer. 1990;65:1478–1482.
Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation and 5-fluorouracil. Cancer. 1981;48:1705–1710.
Treurniet DA, van Mierlo MJ, van Putten WL. Localized unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 1990;18:59–62.
Holyoke ED. New surgical approaches to pancreatic cancer. Cancer. 1981;47:1719–1723.
Dougherty TJ. Photosensitizers: therapy and detection of malignant tumors. Photochem Photobiol. 1987;45:879–889.
Delaney TF, Glatstein E. Photodynamic therapy of cancer. Compr Ther. 1988;14:43–55.
Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc. 1995;42:507–512.
Overholt BF, Panjehpour M. Photodynamic therapy for Barrett’s esophagus. Gastrointest Endosc Clin N Am. 1997;7:207–220.
Gomer CJ, Dougherty TJ. Determination of H-3-and C-14-hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res. 1979;39:146–151.
Tralau CJ, Barr H, Sandemann DR, Barton T, Lewin MR, Bown SG. Aluminum sulfonated phtallocyanine distribution in rodent tumors of the colon, brain, and pancreas. Photochem Photobiol. 1987;46:777–781.
Bown SG. Photodyanmic therapy to scientists and clinicians—one world or two? J Photochem Photobiol B. 1990;6:1–12.
Schroder T, Chen IW, Sperling M, Bell R, Brackett K, Joffe SN. Hematoporphyrin derivative uptake and photodyanamic therapy in pancreatic carcinoma. J Surg Oncol. 1988;38:4–9.
Mang TS, Wieman TJ. Photodynamic therapy in the treatment of pancreatic adenocarcinoma: dihematoporphyrin ether uptake and photobleaching kinetics. Photochem Photobiol. 1987;46:853–858.
Chatlani PT, Toda N, Barr H, Bedwell J, Krasner N, Bown SG. Photodynamic therapy of normal and neoplastic rodent pancreas. Abstract 38 of the Third Biennial Meeting of the International Photodynamic Association; 1990.
Mang TS, Wieman TJ, Crean, DH. Studies on the absence of photodynamic mechanism in the normal pancreas. Proc. SPIE. 1991;1426:188–199.
Whitelaw D, Lees W, Ripley P, Hatfield A, Gillams A, Bown SG. Photodynamic therapy for pancreatic cancer-a clinical pilot study. In: Proceedings of the 7th Biennial Congress International Photodynamic Association; Nantes, France July 7–9, 1998; Abstract 115.
Bhutani MS. Endoscopic ultrasonography in pancreatic disease [review]. Semin Gastrointest Dis. 1998;9:51–60.
Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasoundguided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45:387–393.
Chang KJ, Nguyen PT, Thompson JA, Kurosaki TT, Casey LR, Leung EC. Phase I clinical trial of local immunotherapy (Cytoimplant) delivered by endoscopic ultrasound (EUS) guided fine needle injection (FNI) in patients with advanced pancreatic carcinoma [abstract]. Gastrointest Endosc. 1998;47:AB144.
Bedford RA, Hecht JR, Lahoti S, Abbruzzese J, So L, Kim D. Tolerability and efficacy of direct injection of pancreatic adenocarcinomas with Onyx-015 under endoscopic ultrasound (EUS) guidance [abstract]. Gastrointest Endosc. 2000;51:AB97.
Goldberg SN, Mallery S, Gazelle GS, Brugge WR. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc. 1998;50:392–401.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Lahoti, S. (2002). Photodynamic Therapy and Endoscopic Ultrasound-Guided Therapy for Pancreatic Cancer. In: Evans, D.B., Pisters, P.W.T., Abbruzzese, J.L. (eds) Pancreatic Cancer. M. D. Anderson Solid Tumor Oncology Series. Springer, New York, NY. https://doi.org/10.1007/0-387-21600-6_32
Download citation
DOI: https://doi.org/10.1007/0-387-21600-6_32
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95185-0
Online ISBN: 978-0-387-21600-3
eBook Packages: Springer Book Archive